Dosing and Administration Guide for ARZERRA

Size: px
Start display at page:

Download "Dosing and Administration Guide for ARZERRA"

Transcription

1 Dosing and Administration Guide for ARZERRA Indications ARZERRA (ofatumumab) is indicated: In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate For the treatment of patients with CLL refractory to fludarabine and alemtuzumab Important Safety Information for ARZERRA WARNING: HEPATITIS B VIRUS REACTIVATION AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY Hepatitis B Virus (HBV) reactivation can occur in patients receiving CD20-directed cytolytic antibodies, including ARZERRA, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Progressive Multifocal Leukoencephalopathy (PML) resulting in death can occur in patients receiving CD20-directed cytolytic antibodies, including ARZERRA. Please see additional Important Safety Information on pages and accompanying full Prescribing Information, including Boxed WARNING, To learn more, please visit

2 Welcome Understanding the Difference Between First-Line and FA-Refractory Dosing for ARZERRA (ofatumumab) Table of Contents This guide is designed to be used as a quick reference for the proper dosing of ARZERRA in the treatment of first-line CLL and CLL that is refractory to fludarabine and alemtuzumab (FA). osing for ARZERRA Plus Chlorambucil D for First-Line CLL For your convenience, dosing instructions specific to each indication are organized separately: first-line CLL in the first section (page 4) and FA-refractory CLL in the second section (page 8). General information about product handling is covered in the third section (page 14). Premedication Dosing Recommendations Infusion Rates osing for ARZERRA for CLL Refractory D to Fludarabine and Alemtuzumab Dosing Recommendations If you have any questions regarding ARZERRA or would like to schedule an in-service program, please contact Novartis Pharmaceuticals Corporation or visit us at Premedication Infusion Rates I nfusion Rate Dose Modifications for Infusion Reactions Product Handling Preparation of Solution Dilution Administration How Supplied Storage Support and Resources Safety ARZERRA can cause serious, including fatal, infusion reactions. Infusion reactions occur more frequently with the first 2 infusions. 2 on pages and accompanying full Prescribing Information, including Boxed WARNING, I ndications and Important Safety Information

3 Dosing for ARZERRA (ofatumumab) Plus Chlorambucil Treatment should be continued for a minimum of 3 cycles until best response* or a maximum of cycles Cycle 1 Day mg Cycles 2 up to Day mg Day 1 of each 28-day cycle 1000 mg Chlorambucil: 10 mg/m2 orally days 1-7 of each 28-day cycle1 Please note: The chlorambucil dosing information seen here was evaluated in the pivotal trial, but is not a recommendation from the Dosage and Administration section of the Prescribing Information2 First-Line CLL Dosing Dosing for ARZERRA Plus Chlorambucil for First-Line CLL1 Premedication1 Patients should receive the following premedication 30 minutes to 2 hours prior to each infusion of ARZERRA Oral acetaminophen 1000 mg (or equivalent) plus Oral or IV antihistamine (diphenhydramine 50 mg or cetirizine 10 mg or equivalent) plus IV corticosteroid (prednisolone 50 mg or equivalent) Corticosteroid may be reduced or omitted for subsequent infusions if a grade 3 or greater infusion-related adverse event did not occur during the first 2 infusions Infusion reactions may occur despite premedication In the pivotal trial1: Median number of cycles completed was 6 Dosing Recommendations1 After Cycle 1, ARZERRA is dosed in 28-day cycles. Administer ARZERRA in an environment where facilities to adequately monitor and treat infusion reactions are available Dilute according to instructions on page 14 Administer as an intravenous (IV) infusion according to the schedule outlined above Do not administer as an intravenous push or bolus or as a subcutaneous injection Premedicate before each infusion * The pivotal trial defined best response as 2 consecutive response assessments of stable disease, partial response, or complete response.1 4 on pages and accompanying full Prescribing Information, including Boxed WARNING, 5

4 Dosing for ARZERRA Plus Chlorambucil for First-Line CLL1 Infusion Rates Infusion initiation rates for ARZERRA (ofatumumab) Infusion Initiation Rates Cycle 1, Day 1a (ml/hour) Cycle 1, Day 8b and Cycles 2-c (ml/hour) mg/hour ml/hour Interval After Start of Infusion (min) Cycle 1, Day 1 (300 mg) Cycle 1, Day 8 (1000 mg) Cycles 2 through (1000 mg) Cycle Initiate infusion at a rate of mg/hour if a grade 3 or greater infusion-related adverse event was experienced during the previous infusion In the absence of an infusion-related adverse event, the rate of infusion may be increased every 30 minutes as described in the Infusion Rate Table to the right. Do not exceed the infusion rates in the following Infusion Rate Table Safety Overall, 67% of previously untreated patients experienced one or more symptoms of infusion reactions (10% grade 3, none were fatal). Infusion reactions occurred most frequently during Cycle 1 (56% on Day 1 [6% grade 3] and 23% on Day 8 [3% Grade 3]) and decreased with subsequent infusions. 6 Infusion rates for ARZERRA on pages and accompanying full Prescribing Information, including Boxed WARNING, > Cycle 1, Day 1=300 mg; median duration of infusion=5.2 hours. a b Cycle 1, Day 8=1000 mg; median duration of infusion=4.4 hours. Cycles 2 through =1000 mg; median durations of infusion= 4.2 to 4.4 hours. c Infusion Reactions ARZERRA can cause serious, including fatal, infusion reactions manifesting as bronchospasm, dyspnea, laryngeal edema, pulmonary edema, flushing, hypertension, hypotension, syncope, cardiac events (eg, myocardial ischemia/infarction, acute coronary syndrome, arrhythmia, bradycardia), back pain, abdominal pain, pyrexia, rash, urticaria, angioedema, cytokine release syndrome, and anaphylactoid/ anaphylactic reactions. Infusion reactions occur more frequently with the first 2 infusions. These reactions may result in temporary interruption or withdrawal of treatment. 7

5 Dosing for ARZERRA for CLL Refractory to Fludarabine and Alemtuzumab1 Premedication ARZERRA is administered as infusions over a 24-week period Patients should receive the following premedication 30 minutes to 2 hours prior to each infusion of ARZERRA Weekly Weeks 1-8 Dose 300 mg 1 Doses 2000 mg 2-8 Every 4 Weeks Oral Acetaminophen Weeks, 16, 20, mg or equivalent plus Doses 2000 mg 9- Dosing Recommendations Administer ARZERRA in an environment where facilities to adequately monitor and treat infusion reactions are available Dilute according to instructions on page 14 Administer as an IV infusion according to the schedule outlined above Do not administer as an IV push or bolus or as a subcutaneous injection Premedicate before each infusion Oral or IV Antihistamine Diphenhydramine 50 mg or cetirizine 10 mg or equivalent plus FA-Refractory CLL Dosing Dosing for ARZERRA (ofatumumab) IV Corticosteroid Prednisolone 100 mg or equivalenta o not reduce corticosteroid dose for Doses 1, 2, D and 9. Corticosteroid dose may be reduced as follows: a Doses 3 through 8: Corticosteroid may be reduced or omitted with subsequent infusions if a grade 3 or greater infusion reaction did not occur with the preceding dose Doses 10 through : Administer prednisolone 50 mg to 100 mg or equivalent if a grade 3 or greater infusion reaction did not occur with Dose 9 Infusion reactions may occur despite premedication In a study of FA-refractory patients (study 2), 88% of patients received at least 8 infusions of ARZERRA and 54% received infusions. 8 on pages and accompanying full Prescribing Information, including Boxed WARNING, 9

6 Dosing for ARZERRA for CLL Refractory to Fludarabine and Alemtuzumab1 Infusion Rates Infusion initiation rates for ARZERRA (ofatumumab) Infusion rates for ARZERRA mg/hour ml/hour Interval After Start of Infusion (min) Dose 1 (300 mg) Dose 2 (2000 mg) Dose Doses 3 through (2000 mg) Infusion Initiation Rates 50 Initiate infusion at a rate of mg/hour if a grade 3 or greater infusion-related adverse event was experienced during the previous infusion Dose 1a (ml/hour) Dose 2b (ml/hour) Doses 3-b (ml/hour) > Dose 1=300 mg; median duration of infusion=6.8 hours. a Doses 2 and 3 through =2000 mg; median duration of infusion for Dose 2=6.8 hours; median durations of infusion for Doses 3 through =4.2 to 4.4 hours. b In the absence of an infusion-related adverse event, the rate of infusion may be increased every 30 minutes as described in the Infusion Rate Table to the right. Do not exceed the infusion rates in the following Infusion Rate Table Safety In FA-refractory CLL patients, infusion reactions occurred in 44% of patients on the day of the first infusion (300 mg), 29% on the day of the second infusion (2000 mg), and less frequently during subsequent infusions. 10 on pages and accompanying full Prescribing Information, including Boxed WARNING, Infusion Reactions (cont d) Administer ARZERRA in an environment where facilities to adequately monitor and treat infusion reactions are available. Premedicate with acetaminophen, an antihistamine, and a corticosteroid. Infusion reactions may occur despite premedication. 11

7 Infusion Rate Dose Modifications for Infusion Reactions1 Infusion Rate Dose Modifications Interrupt infusion for infusion reactions of any severity. Treatment can be resumed at the discretion of the treating physician. The following infusion rate modifications can be used as a guide If the infusion reaction resolves or remains less than or equal to grade 2, resume infusion with the following modifications according to the initial grade of the infusion reaction Infuse at one-half of the previous infusion rate Grade 3 or 4: Infuse at a rate of ml/hour Consider permanent discontinuation of ARZERRA (ofatumumab) if the severity of the infusion reaction does not resolve to less than or equal to grade 3 despite adequate clinical intervention Permanently discontinue therapy for patients who develop an anaphylactic reaction to ARZERRA Infusion reactions occur more frequently with the first 2 infusions. Infusion Rate Dose Modifications Grade 1 or 2: After resuming the infusion, the infusion rate may be increased according to the Infusion Rate Tables on pages 6-7 and based on patient tolerance Infusion Reactions (cont d) Interrupt infusion with ARZERRA for infusion reactions of any severity. Institute medical management for severe infusion reactions including angina or other signs and symptoms of myocardial ischemia. If an anaphylactic reaction occurs, immediately and permanently discontinue ARZERRA and initiate appropriate medical treatment. on pages and accompanying full Prescribing Information, including Boxed WARNING, 13

8 Product Handling1 Preparation of Solution Administration Do not shake product Administer ARZERRA in an environment where facilities to adequately monitor and treat infusion reactions are available Inspect parenteral drug products visually for particulate matter and discoloration prior to administration. ARZERRA (ofatumumab) should be a clear to opalescent, colorless solution. The solution should not be used if discolored or cloudy, or if foreign particulate matter is present Dilution 300-mg dose: Withdraw and discard 15 ml from a 1000-mL bag of 0.9% Sodium Chloride Injection, USP. Withdraw 5 ml from each of 3 single-use, 100-mg vials of ARZERRA and add to the bag 1000-mg dose*: Withdraw and discard 50 ml from a 1000-mL bag of 0.9% Sodium Chloride Injection, USP. Withdraw 50 ml from 1 single-use, 1000-mg vial of ARZERRA and add to the bag Do not administer as an IV push or bolus or as a subcutaneous injection Do not mix ARZERRA with, or administer as an infusion with, other medicinal products Administer using an infusion pump and an administration set Flush the IV line with 0.9% Sodium Chloride Injection, USP before and after each dose Start infusion within hours of preparation Discard prepared solution after 24 hours 2000-mg dose : Withdraw and discard 100 ml from a 1000-mL bag of 0.9% Sodium Chloride Injection, USP. Withdraw 50 ml from each of 2 single-use, 1000-mg vials of ARZERRA and add to the bag Product Handling Mix diluted solution by gentle inversion No incompatibilities between ARZERRA and polyvinylchloride or polyolefin bags and administration sets have been observed Not actual size. Prepare all doses in 1000 ml of 0.9% Sodium Chloride Injection, USP. *First-line use only. 14 FA-refractory use only. Please see Important Safety Information on pages and accompanying full Prescribing Information, including Boxed WARNING, 15

9 Product Handling1 How Supplied Carton NDC Number 3 single-use 100-mg/5-mL vials 1 single-use 1000-mg/50-mL vial Vial NDC Carton of 3 vials NDC Vial and carton NDC Dosing Requirements 1 carton of 3 single-use vials (total of 3 vials), are needed for each 300-mg dose 1 carton of 1 single-use vial (total of 1 vial) is needed for each 1000-mg dose 2 cartons of 1 single-use vial (total of 2 vials) are needed for each 2000-mg dose ARZERRA J-Code: J Please see Important Safety Information on pages and accompanying full Prescribing Information, including Boxed WARNING, ARZERRA (ofatumumab) is a sterile, clear to opalescent, colorless, preservative-free liquid concentrate (20 mg/ml) for dilution and intravenous administration provided in single-use glass vials with a rubber stopper (not made with natural rubber latex) and an aluminum overseal. Each vial contains either 100 mg of ARZERRA in 5 ml of solution or 1000 mg of ARZERRA in 50 ml of solution. Storage Store the vials and diluted solution of ARZERRA refrigerated between 2 to 8 C (36 to 46 F) Do not freeze Vials should be protected from light Discard prepared solution after 24 hours ARZERRA is not considered a hazardous material, so there are no biohazard requirements. Dispose per usual hospital/clinic procedures 17

10 Support and Resources Novartis Pharmaceuticals Corporation is committed to providing you with direct access to the resources you and your patients need while treating CLL with ARZERRA (ofatumumab). Contact Information NOW-NOVA ( ) Monday-Friday, 8:30 am-5:00 pm ET Customer Interaction Center Novartis Pharmaceuticals Corporation One Health Plaza East Hanover, NJ Please see Important Safety Information on pages and accompanying full Prescribing Information, including Boxed WARNING, Customized Medical Support You can request personalized assistance from an ARZERRA Medical Sciences Liaison by contacting Novartis Pharmaceuticals Corporation directly via the contact information provided at left. Available Now! Information about ARZERRA is available for you at and for your patients at 19

11 Indications and Important Safety Information Indications ARZERRA (ofatumumab) is indicated: In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate For the treatment of patients with CLL refractory to fludarabine and alemtuzumab Important Safety Information for ARZERRA WARNING: HEPATITIS B VIRUS REACTIVATION AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY Hepatitis B Virus (HBV) reactivation can occur in patients receiving CD20-directed cytolytic antibodies, including ARZERRA, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Progressive Multifocal Leukoencephalopathy (PML) resulting in death can occur in patients receiving CD20-directed cytolytic antibodies, including ARZERRA. Infusion Reactions ARZERRA can cause serious, including fatal, infusion reactions manifesting as bronchospasm, dyspnea, laryngeal edema, pulmonary edema, flushing, hypertension, hypotension, syncope, cardiac events (eg, myocardial ischemia/infarction, acute coronary syndrome, arrhythmia, bradycardia), back pain, abdominal pain, pyrexia, rash, urticaria, angioedema, cytokine release syndrome, and anaphylactoid/anaphylactic reactions. Infusion reactions occur more frequently with the first 2 infusions. These reactions may result in temporary interruption or withdrawal of treatment. 20 on pages 22 and 23 and accompanying full Prescribing Information, including Boxed WARNING, Interrupt infusion with ARZERRA for infusion reactions of any severity. Institute medical management for severe infusion reactions including angina or other signs and symptoms of myocardial ischemia. If an anaphylactic reaction occurs, immediately and permanently discontinue ARZERRA and initiate appropriate medical treatment. Hepatitis B Virus Reactivation Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, has occurred in patients treated with ARZERRA. Cases have been reported in patients who are hepatitis B surface antigen (HBsAg) positive and also in patients who are HBsAg negative but are hepatitis B core antibody (anti-hbc) positive. Reactivation also has occurred in patients who appear to have resolved hepatitis B infection (ie, HBsAg negative, anti-hbc positive, and hepatitis B surface antibody [anti-hbs] positive). HBV reactivation is defined as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA level or detection of HBsAg in a person who was previously HBsAg negative and anti-hbc positive. Reactivation of HBV replication is often followed by hepatitis, ie, increase in transaminase levels and, in severe cases, increase in bilirubin levels, liver failure, and death. Screen all patients for HBV infection by measuring HBsAg and anti-hbc before initiating treatment with ARZERRA. For patients who show evidence of hepatitis B infection (HBsAg positive [regardless of antibody status] or HBsAg negative but anti-hbc positive), consult physicians with expertise in managing hepatitis B regarding monitoring and consideration for HBV antiviral therapy. Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following treatment with ARZERRA. HBV reactivation has been reported for at least months following completion of therapy. 21 Important Safety Information Administer ARZERRA in an environment where facilities to adequately monitor and treat infusion reactions are available. Premedicate with acetaminophen, an antihistamine, and a corticosteroid. Infusion reactions may occur despite premedication.

12 Indications and Important Safety Information (cont d) Hepatitis B Virus Reactivation (cont d) In patients who develop reactivation of HBV while receiving ARZERRA (ofatumumab), immediately discontinue ARZERRA and any concomitant chemotherapy, and institute appropriate treatment. Resumption of ARZERRA in patients whose HBV reactivation resolves should be discussed with physicians with expertise in managing hepatitis B. Insufficient data exist regarding the safety of resuming ARZERRA in patients who develop HBV reactivation. Hepatitis B Virus Infection Fatal infection due to hepatitis B in patients who have not been previously infected has been observed with ARZERRA. Monitor patients for clinical and laboratory signs of hepatitis. Progressive Multifocal Leukoencephalopathy Progressive multifocal leukoencephalopathy (PML) resulting in death has occurred with ARZERRA. Consider PML in any patient with new onset of or changes in pre-existing neurological signs or symptoms. If PML is suspected, discontinue ARZERRA and initiate evaluation for PML including neurology consultation. Tumor Lysis Syndrome Tumor lysis syndrome (TLS), including the need for hospitalization, has occurred in patients treated with ARZERRA. Patients with high tumor burden and/or high circulating lymphocyte counts (> x 109/L) are at greater risk for developing TLS. Consider tumor lysis prophylaxis with anti-hyperuricemics and hydration beginning to 24 hours prior to infusion of ARZERRA. For treatment of TLS, administer aggressive intravenous hydration and anti-hyperuricemic agents, correct electrolyte abnormalities, and monitor renal function. Cytopenias Severe cytopenias, including neutropenia, thrombocytopenia, and anemia, can occur with ARZERRA. Pancytopenia, agranulocytosis, and fatal neutropenic sepsis have occurred in patients who received ARZERRA in combination with chlorambucil. 22 on pages 20 and 21 and accompanying full Prescribing Information, including Boxed WARNING, Grade 3 or 4 late-onset neutropenia (onset at least 42 days after last treatment dose) and/or prolonged neutropenia (not resolved between 24 and 42 days after last treatment dose) were reported in patients who received ARZERRA. Monitor complete blood counts at regular intervals during and after conclusion of therapy, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Immunizations The safety of immunization with live viral vaccines during or following administration of ARZERRA has not been studied. Do not administer live viral vaccines to patients who have recently received ARZERRA. The ability to generate an immune response to any vaccine following administration of ARZERRA has not been studied. Most Common Adverse Reactions In the previously untreated CLL clinical trial, the most common adverse reactions ( 10%, all grades) were infusion reactions (67% for ARZERRA plus chlorambucil vs 0% for chlorambucil) and neutropenia (27% vs 18%). In the single-arm refractory CLL clinical trial, the most common adverse reactions ( 10%, all grades) were neutropenia, pneumonia (23%), pyrexia (20%), cough (19%), diarrhea (18%), anemia (16%), fatigue (15%), dyspnea (14%), rash (14%), nausea (11%), bronchitis (11%), and upper respiratory tract infections (11%). The most common serious adverse reactions were infections (including pneumonia and sepsis), neutropenia, and pyrexia. Infections were the most common adverse reactions leading to drug discontinuation. Laboratory Abnormalities In the previously untreated CLL clinical trial, post-baseline hematologic laboratory abnormalities (all grades) occurring with 5% incidence in patients receiving ARZERRA plus chlorambucil and also 2% more than patients receiving chlorambucil were leukopenia (67% for ARZERRA plus chlorambucil vs 28% for chlorambucil), neutropenia (66% vs 56%), and lymphopenia (52% vs 20%). References: 1. ARZERRA [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, Data on file. GlaxoSmithKline

13 More information available at: Safety ARZERRA (ofatumumab) can cause serious, including fatal, infusion reactions. Infusion reactions occur more frequently with the first 2 infusions. on pages and accompanying full Prescribing Information, including Boxed WARNING, Novartis Pharmaceuticals Corporation East Hanover, New Jersey Novartis 10/15 ARZ-179

Dosing and Administration Guide for ARZERRA

Dosing and Administration Guide for ARZERRA Dosing and Administration Guide for ARZERRA INDICATIONS for ARZERRA (ofatumumab) In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL)

More information

CONTRAINDICATIONS None. (4)

CONTRAINDICATIONS None. (4) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARZERRA safely and effectively. See full prescribing information for ARZERRA. ARZERRA (ofatumumab)

More information

GAZYVA Dosing and Administration Guide

GAZYVA Dosing and Administration Guide GAZYVA Dosing and Administration Guide Indications GAZYVA is a CD20-directed cytolytic antibody and is indicated: In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at

More information

What You Need to Know About ARZERRA (ofatumumab)

What You Need to Know About ARZERRA (ofatumumab) Starting your treatment for chronic lymphocytic leukemia (CLL) What You Need to Know About ARZERRA (ofatumumab) Approved Use ARZERRA is a prescription medication used: With a chemotherapy drug called chlorambucil

More information

ADMINISTRATION GUIDE

ADMINISTRATION GUIDE DOSING AND ADMINISTRATION GUIDE INDICATION LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which

More information

DOSING GUIDE. Indications. Important Safety Information. Enable the immune system. RECOGNIZE. RESPOND.

DOSING GUIDE. Indications. Important Safety Information. Enable the immune system. RECOGNIZE. RESPOND. DOSING GUIDE For patients with unresectable Stage III NSCLC following concurrent CRT For patients with locally advanced or metastatic UC previously treated with platinum-based therapy Enable the immune

More information

DERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:

DERBY-BURTON CANCER NETWORK CONTROLLED DOC NO: OBINUTUZUMAB+CHLORAMBUCIL Regimen RDH; Day 1 and 2 Dose to be given on Ward Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community

More information

DOSAGE FORMS AND STRENGTHS mg/40 ml (25 mg/ml) single-dose vial. (3)

DOSAGE FORMS AND STRENGTHS mg/40 ml (25 mg/ml) single-dose vial. (3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GAZYVA safely and effectively. See full prescribing information for GAZYVA. GAZYVA (obinutuzumab)

More information

GAZYVA for Chronic Lymphocytic Leukemia (CLL)

GAZYVA for Chronic Lymphocytic Leukemia (CLL) GAZYVA for Chronic Lymphocytic Leukemia (CLL) GAZYVA is a prescription medicine used with the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous

More information

Arzerra. Arzerra (ofatumumab) Description

Arzerra. Arzerra (ofatumumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.03 Subject: Arzerra Page: 1 of 5 Last Review Date: June 22, 2017 Arzerra Description Arzerra (ofatumumab)

More information

Gazyva (obinutuzumab)

Gazyva (obinutuzumab) STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination

More information

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults

More information

PHARMACY DOSING AND ORDERING GUIDE

PHARMACY DOSING AND ORDERING GUIDE PHARMACY DOSING AND ORDERING GUIDE FIRST AND ONLY APPROVED TREATMENT FOR PATIENTS WITH VOD WITH RENAL OR PULMONARY DYSFUNCTION POST HSCT VOD=veno-occlusive disease Indication Defitelio (defibrotide sodium)

More information

BLA /S-017 BLA /S-018 SUPPLEMENT APPROVAL

BLA /S-017 BLA /S-018 SUPPLEMENT APPROVAL DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 BLA 125486/S-017 BLA 125486/S-018 SUPPLEMENT APPROVAL Genentech, Inc. Attention: Jerald Grace, PharmD Regulatory

More information

The only biologic approved to treat SLE: now with multiple delivery options

The only biologic approved to treat SLE: now with multiple delivery options The only biologic approved to treat SLE: now with multiple delivery options BENLYSTA (belimumab) Autoinjector SC Prefilled syringe IV Intravenous infusion Consider the options: visit Belimumab.com INDICATION

More information

PRODUCT INFORMATION 1 ABOUT THIS GUIDE DOSAGE FORM AND STRENGTH STORAGE AND HANDLING

PRODUCT INFORMATION 1 ABOUT THIS GUIDE DOSAGE FORM AND STRENGTH STORAGE AND HANDLING DOSING GUIDE INDICATION ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of

More information

YONDELIS (trabectedin) DOSING & ADMINISTRATION GUIDE

YONDELIS (trabectedin) DOSING & ADMINISTRATION GUIDE YONDELIS (trabectedin) DOSING & ADMINISTRATION GUIDE INDICATION YONDELIS (trabectedin) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received

More information

GUIDELINES FOR WEIGHT-BASED DOSING AND INFUSION

GUIDELINES FOR WEIGHT-BASED DOSING AND INFUSION GUIDELINES FOR WEIGHT-BASED DOSING AND INFUSION Includes Example dose calculation wheel Preparation and administration information for healthcare professionals Please see enclosed full Prescribing Information,

More information

BC Cancer Protocol Summary for Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and rituximab

BC Cancer Protocol Summary for Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and rituximab BC Cancer Protocol Summary for Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and rituximab Protocol Code Tumour Group Contact Physicians LYCLLFLUDR Lymphoma Dr.

More information

FULL PRESCRIBING INFORMATION: CONTENTS*

FULL PRESCRIBING INFORMATION: CONTENTS* HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CAMPATH safely and effectively. See full prescribing information for CAMPATH. CAMPATH (alemtuzumab)

More information

LEMTRADA REMS Education Program for Healthcare Facilities

LEMTRADA REMS Education Program for Healthcare Facilities For Healthcare Facilities LEMTRADA REMS Education Program for Healthcare Facilities This Educational Piece Includes Information About: The LEMTRADA REMS Program requirements to implement in your healthcare

More information

Gazyva. Gazyva (obinutuzumab) Description

Gazyva. Gazyva (obinutuzumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: September 15, 2016 Gazyva Description Gazyva (obinutuzumab)

More information

BC Cancer Protocol Summary for the Treatment of rituximabrefractory Follicular Lymphoma (FL) with obinutuzumab in combination with Bendamustine

BC Cancer Protocol Summary for the Treatment of rituximabrefractory Follicular Lymphoma (FL) with obinutuzumab in combination with Bendamustine BC Cancer Protocol Summary for the Treatment of rituximabrefractory Follicular Lymphoma (FL) with obinutuzumab in combination with Bendamustine Protocol Code Tumour Group Contact Physician ULYOBBEND Lymphoma

More information

Administration Tear Pad

Administration Tear Pad for WG and Administration Tear Pad The first and ONLy FDA-approved therapy for Wegener s granulomatosis (WG) AND microscopic polyangiitis () Inside: Patient Checklist and Chart Record Preparation and Administration

More information

Pharmacy Instructions for Preparation

Pharmacy Instructions for Preparation MARQIBO (vincristine sulfate LIPOSOME injection) Pharmacy Instructions for Preparation Important Information for Preparation 1 The instructions for the constitution of MARQIBO are provided in each kit.

More information

PNH ahus. Dosing and Administration. For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus) patients

PNH ahus. Dosing and Administration. For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus) patients For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus) patients PNH ahus Dosing and Administration Soliris is indicated for the treatment of patients with paroxysmal

More information

Gazyva. Gazyva (obinutuzumab) Description

Gazyva. Gazyva (obinutuzumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: March 16, 2018 Gazyva Description Gazyva (obinutuzumab)

More information

To learn more, visit ISTODAX.com or speak with your local Celgene representative

To learn more, visit ISTODAX.com or speak with your local Celgene representative DOSING GUIDE FOR NURSES AND PHARMACISTS Important facts you should know about: Dosing Dosing Modifications Administration Safety To learn more, visit ISTODAX.com or speak with your local Celgene representative

More information

Chronic Lymphocytic Leukemia Update. Learning Objectives

Chronic Lymphocytic Leukemia Update. Learning Objectives Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend

More information

PNH ahus gmg. Dosing and Administration Guide

PNH ahus gmg. Dosing and Administration Guide Injection for Intravenous Use PNH ahus gmg For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus), and generalized Myasthenia Gravis (gmg) patients Dosing and Administration

More information

DOSING & ADMINISTRATION FOR DARZALEX (daratumumab)

DOSING & ADMINISTRATION FOR DARZALEX (daratumumab) JUNE 2017 UPDATE DOSING & ADMINISTRATION FOR DARZALEX (daratumumab) Indications and mechanisms of action 1 How DARZALEX is supplied DARZALEX (daratumumab) is indicated: in combination with lenalidomide

More information

NCCP Chemotherapy Regimen. Obinutuzumab and Chlorambucil Therapy

NCCP Chemotherapy Regimen. Obinutuzumab and Chlorambucil Therapy INDICATIONS FOR USE: Obinutuzumab INDICATION ICD10 Regimen Code *Reimbursement Indicator Treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities

More information

Antiemetic protocol for rare emetogenic chemotherapy - see protocol SCNAUSEA

Antiemetic protocol for rare emetogenic chemotherapy - see protocol SCNAUSEA BCCA Protocol Summary for Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma with obinutuzumab and Chlorambucil Protocol Code Tumour Group Contact Physician

More information

Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case

Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Available

More information

CONTRAINDICATIONS None (4)

CONTRAINDICATIONS None (4) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRUXIMA safely and effectively. See full prescribing information for TRUXIMA. TRUXIMA (rituximab-abbs)

More information

Final Labeling Text

Final Labeling Text 1.14.2.3 Final Labeling Text HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Rituxan safely and effectively. See full prescribing information for

More information

IN A STUDY OF PATIENTS WITH GPA & MPA RITUXIMAB REGIMEN DEMONSTRATED CLINICALLY SIGNIFICANT REDUCTION OF MAJOR RELAPSE RATE VS AZA 1

IN A STUDY OF PATIENTS WITH GPA & MPA RITUXIMAB REGIMEN DEMONSTRATED CLINICALLY SIGNIFICANT REDUCTION OF MAJOR RELAPSE RATE VS AZA 1 FDA Approved for follow-up treatment 1 * IN A STUDY OF PATIENTS WITH GPA & MPA RITUXIMAB REGIMEN DEMONSTRATED CLINICALLY SIGNIFICANT REDUCTION OF MAJOR RELAPSE RATE VS AZA 1 Rituximab regimen=roche-manufactured,

More information

Ocrevus. (ocrelizumab) New Product Slideshow

Ocrevus. (ocrelizumab) New Product Slideshow Ocrevus (ocrelizumab) New Product Slideshow Introduction Brand name: Ocrevus Generic name: Ocrelizumab Pharmacological class: CD20-directed cytolytic monoclonal antibody Strength and Formulation: 30mg/mL;

More information

DOSING AND INFORMATION GUIDE LEAPS AHEAD

DOSING AND INFORMATION GUIDE LEAPS AHEAD DOSING AND INFORMATION GUIDE In patients with WT RAS* mcrc 1 VECTIBIX (panitumumab) LEAPS AHEAD 5.6-month increase in median OS with FOLFOX vs FOLFOX alone 1 Spot the difference. CHOOSE VECTIBIX PRIME

More information

Rituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description

Rituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.96 Subject: Rituxan Hycela Page: 1 of 5 Last Review Date: September 15, 2017 Rituxan Hycela Description

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Arzerra 100 mg concentrate for solution for infusion Arzerra 1000 mg concentrate for solution for infusion 2. QUALITATIVE AND

More information

DOSING AND ORDERING GUIDE

DOSING AND ORDERING GUIDE DOSING AND ORDERING GUIDE A reference guide for dosing, ordering, and product returns, plus support services for you and your patients INDICATION EMPLICITI is indicated in combination with lenalidomide

More information

RiTUXimab 375 mg/m 2 Therapy-7 day

RiTUXimab 375 mg/m 2 Therapy-7 day RiTUXimab 375 mg/m 2 Therapy-7 day This regimen supercedes NCCP Regimen 00208 rituximab 375mg/m2 therapy-follicular lymphoma as of February 2019 INDICATIONS FOR USE: Regimen *Reimbursement INDICATION ICD10

More information

INFUSING. ORENCIA (abatacept) IV INDICATION/USAGE. Your go-to guide for preparing and administering an ORENCIA intravenous (IV) infusion

INFUSING. ORENCIA (abatacept) IV INDICATION/USAGE. Your go-to guide for preparing and administering an ORENCIA intravenous (IV) infusion INFUSING ORENCIA (abatacept) IV Your go-to guide for preparing and administering an ORENCIA intravenous (IV) infusion INDICATION/USAGE Adult Rheumatoid Arthritis (RA): ORENCIA is indicated for reducing

More information

GAZYVA for Previously Untreated Follicular Lymphoma

GAZYVA for Previously Untreated Follicular Lymphoma NOW APPROVED GAZYVA for Previously Untreated Follicular Lymphoma Studied head-to-head vs rituximab * in stage II bulky, III, and IV patients 1 * GAZYVA and rituximab were each combined with bendamustine,

More information

(galsulfase) DOSING & ADMINISTRATION GUIDE

(galsulfase) DOSING & ADMINISTRATION GUIDE (galsulfase) DOSING & ADMINISTRATION GUIDE Indication: (galsulfase) is indicated for patients with Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome). has been shown to improve walking and stair-climbing

More information

BLINCYTO (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014

BLINCYTO (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BLINCYTO safely and effectively. See full prescribing information for BLINCYTO. BLINCYTO (blinatumomab)

More information

AUSTRALIAN PRODUCT INFORMATION Gazyva (obinutuzumab)

AUSTRALIAN PRODUCT INFORMATION Gazyva (obinutuzumab) AUSTRALIAN PRODUCT INFORMATION Gazyva (obinutuzumab) WARNING Progressive Multifocal Leucoencephalopathy Progressive Multifocal Leukoencephalopathy (PML) including fatal PML can occur in patients receiving

More information

O-CHOP with Obinutuzumab maintenance

O-CHOP with Obinutuzumab maintenance O-CHOP with Obinutuzumab maintenance Indication Adult patients with untreated advanced follicular lymphoma with Follicular Lymphoma International Prognostic Index (FLIPI) score of 2 or above. (NICE TA513)

More information

DOSING AND ADMINISTRATION GUIDE

DOSING AND ADMINISTRATION GUIDE DOSING AND ADMINISTRATION GUIDE for ADCETRIS in classical Hodgkin lymphoma (chl) ADCETRIS is indicated for the treatment of: Previously untreated Stage III/IV chl Adult patients with previously untreated

More information

A Guide for Nurses and Pharmacists CYRAMZA DOSING AND ADMINISTRATION

A Guide for Nurses and Pharmacists CYRAMZA DOSING AND ADMINISTRATION A Guide for Nurses and Pharmacists CYRAMZA DOSING AND ADMINISTRATION CYRAMZA (ramucirumab), in combination with docetaxel, is indicated for the treatment of patients with metastatic non-small cell lung

More information

HERCEPTIN (trastuzumab) for injection, for intravenous use Initial U.S. Approval: 1998

HERCEPTIN (trastuzumab) for injection, for intravenous use Initial U.S. Approval: 1998 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Herceptin safely and effectively. See full prescribing information for Herceptin. HERCEPTIN (trastuzumab)

More information

Infusion Checklist for OCREVUS in relapsing or primary progressive forms of multiple sclerosis

Infusion Checklist for OCREVUS in relapsing or primary progressive forms of multiple sclerosis Infusion Checklist for OCREVUS in relapsing or primary progressive forms of multiple sclerosis 1 PREINFUSION COUNSELING Provide medication guide and review with your patient Inform patients about the signs

More information

Administration Tear Pad

Administration Tear Pad GPA & MPA Rituxan for GPA and MPA Administration Tear Pad RITUXAN, IN COMBINATION WITH GLUCOCORTICOIDS, IS THE ONLY FDA-APPROVED INDUCTION THERAPY FOR GRANULOMATOSIS WITH POLYANGIITIS (GPA) AND MICROSCOPIC

More information

NCCP Chemotherapy Regimen. Brentuximab vedotin Monotherapy

NCCP Chemotherapy Regimen. Brentuximab vedotin Monotherapy Brentuximab INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): Following autologous stem cell

More information

ULYRICE. Protocol Code. Lymphoma. Tumour Group. Dr. Laurie Sehn. Contact Physician

ULYRICE. Protocol Code. Lymphoma. Tumour Group. Dr. Laurie Sehn. Contact Physician BCCA Protocol Summary for the Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and rituximab Protocol Code Tumour Group

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 ARZERRA 100 mg, concentrate for solution for infusion B/3 (CIP code: 577 117-9) B/10 (CIP code: 577

More information

NCCP Chemotherapy Regimen. Obinutuzumab Maintenance Therapy following O-Bendamustine therapy

NCCP Chemotherapy Regimen. Obinutuzumab Maintenance Therapy following O-Bendamustine therapy Obinutuzumab following O-Bendamustine therapy INDICATIONS FOR USE: INDICATION Obinutuzumab maintenance therapy is indicated in patients with follicular lymphoma (FL) who have responded to induction treatment

More information

Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities

Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with

More information

KHAPZORY (levoleucovorin) for injection, for intravenous use Initial U.S. Approval: 1952 (d,l-leucovorin)

KHAPZORY (levoleucovorin) for injection, for intravenous use Initial U.S. Approval: 1952 (d,l-leucovorin) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KHAPZORY safely and effectively. See full prescribing information for KHAPZORY. KHAPZORY (levoleucovorin)

More information

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound

More information

BLINCYTO (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014

BLINCYTO (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BLINCYTO safely and effectively. See full prescribing information for BLINCYTO. BLINCYTO (blinatumomab)

More information

Step-by-step instructions for intravenous (iv) infusions for patients with:

Step-by-step instructions for intravenous (iv) infusions for patients with: Step-by-step instructions for intravenous (iv) infusions for patients with: Rheumatoid Arthritis (RA) Systemic Juvenile Idiopathic Arthritis (sjia) Polyarticular Juvenile Idiopathic Arthritis (pjia) Please

More information

OCREVUS TM (ocrelizumab) injection, for intravenous use Initial U.S. Approval: 2017

OCREVUS TM (ocrelizumab) injection, for intravenous use Initial U.S. Approval: 2017 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OCREVUS safely and effectively. See full prescribing information for OCREVUS. OCREVUS TM (ocrelizumab)

More information

Get the facts about WG, MPA, and Rituxan.

Get the facts about WG, MPA, and Rituxan. First approved treatment for adults with Wegener s granulomatosis (WG) and microscopic polyangiitis (MPA) Get the facts about WG, MPA, and Rituxan. {Brenda, living with Wegener s granulomatosis} INDICATION

More information

Dosing and Administration Guide

Dosing and Administration Guide Dosing and Administration Guide NULOJIX (belatacept) is available as 250 mg lyophilized powder for injection, for intravenous use. Indication r NULOJIX (in combination with basiliximab induction, mycophenolate

More information

CSL Behring LLC Albuminar -25 US Package Insert Albumin (Human) USP, 25% Revised: 01/2008 Page 1

CSL Behring LLC Albuminar -25 US Package Insert Albumin (Human) USP, 25% Revised: 01/2008 Page 1 Page 1 CSL Behring Albuminar -25 Albumin (Human) USP, 25% R x only DESCRIPTION Albuminar -25, Albumin (Human) 25%, is a sterile aqueous solution of albumin obtained from large pools of adult human venous

More information

BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN)

BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN) BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code: Tumour Group: Contact Physician: UBRAJTTW Breast Dr. Angela Chan ELIGIBILITY:

More information

*Sections or subsections omitted from the full prescribing information are not listed.

*Sections or subsections omitted from the full prescribing information are not listed. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GIAPREZA TM safely and effectively. See full prescribing information for GIAPREZA. GIAPREZA (angiotensin

More information

R-Gemcitabine (1000mg/m 2 ) Oxaliplatin Therapy i - 14 day

R-Gemcitabine (1000mg/m 2 ) Oxaliplatin Therapy i - 14 day R-Gemcitabine (1000mg/m 2 ) Oxaliplatin i - 14 day INDICATIONS FOR USE: Regimen Code INDICATION ICD10 Relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem

More information

Idelalisib and RiTUXimab Therapy INDICATIONS FOR USE: EXCLUSIONS: Hypersensitivity to idelalisib, rituximab or any of the excipients.

Idelalisib and RiTUXimab Therapy INDICATIONS FOR USE: EXCLUSIONS: Hypersensitivity to idelalisib, rituximab or any of the excipients. INDICATIONS FOR USE: INDICATION In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): who have received at least one prior therapy or as first line

More information

HIGHLIGHTS OF PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use North American Coral Snake Antivenin (Equine) safely and effectively. See full prescribing information

More information

OCREVUS (ocrelizumab) Injection, for Intravenous Use

OCREVUS (ocrelizumab) Injection, for Intravenous Use OCREVUS (ocrelizumab) Injection, for Intravenous Use Heidi Crayton, MD Medical Director Multiple Sclerosis Center of Greater Washington Vienna, VA OCR/071916/0181(1) Disclaimer This program is presented

More information

Rasburicase 1.5 mg/ml powder and solvent for concentrate for solution for infusion. FASTURTEC

Rasburicase 1.5 mg/ml powder and solvent for concentrate for solution for infusion. FASTURTEC For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory This package insert is continually updated. Please read carefully before using a new pack. Rasburicase 1.5 mg/ml powder

More information

NCCP Chemotherapy Regimen. Brentuximab vedotin Monotherapy

NCCP Chemotherapy Regimen. Brentuximab vedotin Monotherapy INDICATIONS FOR USE: INDICATION Brentuximab Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): Following autologous stem cell transplant (ASCT) or Following at least two

More information

Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities

Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with

More information

ACTEMRA SC formulation is not intended for intravenous administration.

ACTEMRA SC formulation is not intended for intravenous administration. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. ACTEMRA (tocilizumab)

More information

Reimbursement Guide. Hospital Outpatient. Please see Important Safety Information on page 2 and click here for full Prescribing Information.

Reimbursement Guide. Hospital Outpatient. Please see Important Safety Information on page 2 and click here for full Prescribing Information. Reimbursement Guide Hospital Outpatient Information provided in this resource is for informational purposes only and does not guarantee that codes will be appropriate or that coverage and reimbursement

More information

HELPING YOU AND YOUR PATIENTS TALK OPENLY ABOUT MODERATELY TO SEVERELY ACTIVE RA

HELPING YOU AND YOUR PATIENTS TALK OPENLY ABOUT MODERATELY TO SEVERELY ACTIVE RA SIMPONI ARIA (golimumab) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) in combination with MTX, active psoriatic arthritis, and active ankylosing

More information

SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin)

SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin) SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin) Please see Important Safety Information on pages 14 and 15 and accompanying full Prescribing Information. YONDELIS (trabectedin) STUDY DESIGN INDICATION

More information

BESPONSA (inotuzumab ozogamicin)

BESPONSA (inotuzumab ozogamicin) BESPONSA (inotuzumab ozogamicin) Fact Sheet BESPONSA (inotuzumab ozogamicin) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody (mab) targeting CD22, a cell surface antigen expressed

More information

Reimbursement Guide. Hospital Outpatient. Please see Important Safety Information on page 2 and click here for full Prescribing Information.

Reimbursement Guide. Hospital Outpatient. Please see Important Safety Information on page 2 and click here for full Prescribing Information. Reimbursement Guide Hospital Outpatient Information provided in this resource is for informational purposes only and does not guarantee that codes will be appropriate or that coverage and reimbursement

More information

PRODUCT PROFILE. Clinical evidence for formulary and pathway considerations

PRODUCT PROFILE. Clinical evidence for formulary and pathway considerations PRODUCT PROFILE Clinical evidence for formulary and pathway considerations INDICATION EMPLICITI TM (elotuzumab) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients

More information

An Important Message for Patients and Healthcare Professionals Who Depend on IMBRUVICA (ibrutinib)

An Important Message for Patients and Healthcare Professionals Who Depend on IMBRUVICA (ibrutinib) An Important Message for Patients and Healthcare Professionals Who Depend on IMBRUVICA (ibrutinib) IMBRUVICA (ibrutinib) is a meaningful and important treatment option for patients with chronic lymphocytic

More information

ACTEMRA (tocilizumab) injection, for intravenous use injection, for subcutaneous use Initial U.S. Approval: 2010

ACTEMRA (tocilizumab) injection, for intravenous use injection, for subcutaneous use Initial U.S. Approval: 2010 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. ACTEMRA (tocilizumab)

More information

ACTEMRA can be used alone following discontinuation of glucocorticoids.

ACTEMRA can be used alone following discontinuation of glucocorticoids. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (tocilizumab) injection, for intravenous

More information

DOSING AND INFUSION GUIDE

DOSING AND INFUSION GUIDE DOSING AND INFUSION GUIDE VPRIV has up to 5 years of data from the largest clinical trial program of an ERT for type 1 Gaucher disease (GD1) 1,2 * *Study 044 was a long-term, open-label extension study

More information

Preparation and Administration

Preparation and Administration Preparation and Administration A guide for healthcare professionals XOLAIR IS INDICATED FOR: Adults and adolescents (aged 12 years) with moderate-to-severe persistent asthma who have a positive skin test

More information

Taiwan PI for Velcade. (Followed as USPI version Jun 2017; Local version 1701)

Taiwan PI for Velcade. (Followed as USPI version Jun 2017; Local version 1701) Taiwan PI for Velcade (Followed as USPI version Jun 2017; Local version 1701) 1 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Multiple Myeloma Velcade (bortezomib) in combination with other

More information

Medication Policy Manual. Topic: Arzerra, ofatumumab Date of Origin: January 15, 2010

Medication Policy Manual. Topic: Arzerra, ofatumumab Date of Origin: January 15, 2010 Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru196 Topic: Arzerra, ofatumumab Date of Origin: January 15, 2010 Committee Approval Date: January

More information

PRODUCT MONOGRAPH. obinutuzumab. 25 mg/ml Concentrate for Solution for Infusion. Professed Standard. Antineoplastic

PRODUCT MONOGRAPH. obinutuzumab. 25 mg/ml Concentrate for Solution for Infusion. Professed Standard. Antineoplastic PRODUCT MONOGRAPH Pr GAZYVA obinutuzumab 25 mg/ml Concentrate for Solution for Infusion Professed Standard Antineoplastic Hoffmann-La Roche Limited 7070 Mississauga Rd. Mississauga, Ontario, Canada L5N

More information

Reference ID:

Reference ID: HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. KYPROLIS (carfilzomib)

More information

A study population in need of additional treatment options 1,2. The following serious adverse events (AEs) are discussed in greater detail below:

A study population in need of additional treatment options 1,2. The following serious adverse events (AEs) are discussed in greater detail below: For chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab EXPAND YOUR OPTIONS A study population in need of additional treatment options 1,2 5 median prior therapies 59% 93% 100%

More information

(212) (347)

(212) (347) EMBARGOED FOR MONDAY, JUNE 21, 2010: 3:00 P.M. EST For immediate release: June 21, 2010 Media Contact: Curtis Allen (212) 733-2096 (347) 443-5252 Investors Contact: Suzanne Harnett (212) 733-8009 Pfizer

More information

DOSING & ADMINISTRATION GUIDE

DOSING & ADMINISTRATION GUIDE DOSING & ADMINISTRATION GUIDE EXONDYS51.com INDICATION 1 EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is

More information

For the use of only Oncologist or a Cancer Hospital or a laboratory Doxorubicin Hydrochloride Liposome Injection 2 mg/ml KEMODOXA

For the use of only Oncologist or a Cancer Hospital or a laboratory Doxorubicin Hydrochloride Liposome Injection 2 mg/ml KEMODOXA For the use of only Oncologist or a Cancer Hospital or a laboratory Doxorubicin Hydrochloride Liposome Injection 2 mg/ml KEMODOXA COMPOSITION Each ml contains: Doxorubicin Hydrochloride IP...2 mg Water

More information

(angiotensin II) injection for intravenous infusion

(angiotensin II) injection for intravenous infusion ADMINISTERING GIAPREZA TM (angiotensin II) injection for intravenous infusion Visit www.giapreza.com INITIATE Recommended starting dose of GIAPREZA is 20 ng/kg/min, which is equivalent to 0.02 mcg/kg/min

More information

ACTEMRA IV Dosing & Administration Pocket Guide

ACTEMRA IV Dosing & Administration Pocket Guide IMPORTANT SAFETY INFORMATION BOXED WARNING Serious Infections Serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, and other opportunistic

More information